TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension. It consists of 3 phases: Screening, Treatment and Follow-up. During the Screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the Baseline visit, the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study, patients will be asked to repeat the right heart catheterization and exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
C: Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort
D: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension. It consists of 3 phases: Screening, Treatment and Follow-up. During the Screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the Baseline visit, the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study, patients will be asked to repeat the right heart catheterization and exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
B: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan 10 mg; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Bosentan administration; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension. It consists of 3 phases: Screening, Treatment and Follow-up. During the Screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the Baseline visit, the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study, patients will be asked to repeat the right heart catheterization and exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
C: Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort
D: Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity
Brief Summary: The three purposes of this study are the following:

* To compare during a 6-month treatment the safety and effectiveness of idrabiotaparinux (SSR126517) with that of idraparinux (SR34006), taking into account new events of deep venous thrombosis (DVT) and pulmonary embolism (PE), and bleeding risk;
* To compare the activities of idrabiotaparinux and idraparinux directly in blood during and after a 6-month treatment;
* To check the ability of avidin (SSR29261) to reverse the blood thinning activity of idrabiotaparinux at the end of a 6-month treatment period.


Options:
A: Arm Label: SRI 15mg (15 mL/min ≤ CLCR < 20mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Arm Label: MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min); Type: EXPERIMENTAL; Interventions: Drug: 30mg DU-176b | Arm Label: Fondaparinux (20 mL/min ≤ CLCR < 30mL/min); Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: SRI 15mg (20 mL/min ≤ CLCR < 30mL/min); Type: EXPERIMENTAL; Interventions: Drug: 15mg DU-176b | Intervention Type: DRUG; Name: 15mg DU-176b; Assigned to Arm(s): SRI 15mg (15 mL/min ≤ CLCR < 20mL/min), SRI 15mg (20 mL/min ≤ CLCR < 30mL/min) | Intervention Type: DRUG; Name: 30mg DU-176b; Assigned to Arm(s): MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min) | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)
B: Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux
D: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity
Brief Summary: The three purposes of this study are the following:

* To compare during a 6-month treatment the safety and effectiveness of idrabiotaparinux (SSR126517) with that of idraparinux (SR34006), taking into account new events of deep venous thrombosis (DVT) and pulmonary embolism (PE), and bleeding risk;
* To compare the activities of idrabiotaparinux and idraparinux directly in blood during and after a 6-month treatment;
* To check the ability of avidin (SSR29261) to reverse the blood thinning activity of idrabiotaparinux at the end of a 6-month treatment period.


Options:
A: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A
B: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux
C: Arm Label: Andexanet; Type: EXPERIMENTAL; Interventions: Biological: Andexanet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Andexanet; Assigned to Arm(s): Andexanet | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: SanOrg34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: LMW heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin K antagonist (VKA); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure
Brief Summary: The purpose of this study is to determine whether extra education of patients with chronic heart failure can reduce 6 months readmission rate to hospital.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Do CHANGE | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Do CHANGE; Assigned to Arm(s): Intervention
B: Intervention Type: BEHAVIORAL; Name: 6 months readmission rate to hospital; Assigned to Arm(s): N/A
C: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational website.; Type: EXPERIMENTAL; Interventions: Other: Educational website (in addition to usual care). | Arm Label: Website and interactive platform with telemonitoring.; Type: EXPERIMENTAL; Interventions: Other: Website and interactive platform with telemonitoring. | Intervention Type: OTHER; Name: Educational website (in addition to usual care).; Assigned to Arm(s): Educational website. | Intervention Type: OTHER; Name: Website and interactive platform with telemonitoring.; Assigned to Arm(s): Website and interactive platform with telemonitoring.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure
Brief Summary: The purpose of this study is to determine whether extra education of patients with chronic heart failure can reduce 6 months readmission rate to hospital.


Options:
A: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Intervention Type: DEVICE; Name: Electronic health record and messaging system; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: 6 months readmission rate to hospital; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily
Brief Summary: Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily


Options:
A: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily
Brief Summary: Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily


Options:
A: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
D: Arm Label: clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): clopidogrel | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfer of Skills From LapSimGyn VR-Simulator to a Laparoscopic Salpingectomy
Brief Summary: The purpose is to determine if skills obtained by training in the laparoscopic virtual reality simulator LapSimGyn can be transferred to a real laparoscopic operation measured as improved score in a technical skills assessment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: LapSimGyn training until expert proficiency level is reached | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional clinical education | Intervention Type: BEHAVIORAL; Name: LapSimGyn training until expert proficiency level is reached; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Traditional clinical education; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: robot therapy (ARMin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional therapy | Intervention Type: DEVICE; Name: robot therapy (ARMin); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional therapy; Assigned to Arm(s): 2
C: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control
D: Arm Label: MusicGlove Group; Type: EXPERIMENTAL; Interventions: Device: MusicGlove | Arm Label: Control Group for Music Glove; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional hand exercise | Arm Label: Resonating Arm Exerciser (RAE); Type: EXPERIMENTAL; Interventions: Device: Resonating Arm Exerciser | Arm Label: Control Group for RAE; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Arm Exercise | Intervention Type: OTHER; Name: Conventional hand exercise; Assigned to Arm(s): Control Group for Music Glove | Intervention Type: DEVICE; Name: MusicGlove; Assigned to Arm(s): MusicGlove Group | Intervention Type: OTHER; Name: Conventional Arm Exercise; Assigned to Arm(s): Control Group for RAE | Intervention Type: DEVICE; Name: Resonating Arm Exerciser; Assigned to Arm(s): Resonating Arm Exerciser (RAE)

Answer: A